Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Core Viewpoint - Ono Pharmaceutical Co., Ltd. has received approval from the European Commission for ROMVIMZA™ (vimseltinib) to treat adult patients with symptomatic tenosynovial giant cell tumor (TGCT) in the EU [1] Group 1: Product Approval - The European Commission approved ROMVIMZA™ for adult patients with symptomatic TGCT [1] - The approval is specifically for patients who have experienced clinically relevant physical function deterioration and have exhausted surgical options or face unacceptable risks from surgery [1]